Effective 1 May 2026, amendments to China’s Maritime Code—specifically Article 93—reassign primary liability for uncollected cargo at destination ports from consignees to shippers. This legal shift directly impacts exporters of high-value medical equipment, including CT scanners, ultrasound systems, and dental imaging devices, particularly under FOB and CFR trade terms.

Key Legal Change Effective 1 May 2026

As of 1 May 2026, the revised Maritime Code of the People’s Republic of China enters into force. Article 93 explicitly establishes shipper liability as primary when cargo remains uncollected at the discharge port—replacing the prior regime where consignee responsibility applied. The provision applies uniformly to international shipments governed by Chinese law, including those involving African and Southeast Asian importers. Its scope covers scenarios such as customs clearance delays or outright cargo abandonment by overseas buyers.

Impact Across the Medical Equipment Export Ecosystem

Direct trading enterprises

Exporters engaging in FOB/CFR contracts now bear first-line financial exposure—including demurrage, re-export costs, and LC discrepancies—if foreign buyers fail to collect goods. Contractual risk allocation previously assumed consignee compliance; this is no longer tenable without explicit renegotiation.

Manufacturing enterprises

Original equipment manufacturers (OEMs) exporting under their own name—or via affiliated trading arms—face heightened exposure during order fulfillment and documentation handover. Delivery timelines, bill-of-lading issuance, and release instructions must now incorporate proactive contingency planning for destination-side non-performance.

Supply chain service providers

Freight forwarders and logistics integrators supporting medtech exports must revise standard operating procedures, especially regarding cargo release protocols, insurance coordination, and real-time visibility into consignee readiness. Their advisory role on contractual risk transfer gains strategic importance.

Procurement and sourcing enterprises

Entities managing global procurement for healthcare facilities or distributors must reassess supplier selection criteria—not only for technical compliance but also for contractual resilience, including evidence of updated Incoterms alignment and cargo insurance coverage extending to post-discharge liability.

Critical Actions for Exporters and Compliance Teams

Revise Incoterms usage and contract clauses

FOB and CFR terms no longer shield exporters from destination port liabilities under the new regime. Parties should consider shifting to CIF or DAP where control over delivery completion and insurance scope can be retained—or insert express clauses allocating uncollected-cargo risk back to the buyer, subject to enforceability under applicable law.

Expand marine cargo insurance coverage

Standard marine policies typically exclude liability arising from consignee non-collection. Exporters must verify whether their current policies cover demurrage, storage, and repatriation costs triggered by Article 93 scenarios—and negotiate extensions where gaps exist.

Strengthen pre-shipment due diligence on buyers

Enhanced vetting of importer creditworthiness, customs agent reliability, and local regulatory capacity—especially in African and Southeast Asian markets—is now a compliance prerequisite. Documentation requirements, such as advance proof of import permits or customs bond arrangements, should be integrated into order acceptance workflows.

Update internal credit and finance controls

Finance teams must adjust risk provisioning models to reflect potential write-offs from abandoned shipments. Credit limits, LC confirmation practices, and payment term structures should be reviewed in light of increased operational and financial exposure under the revised liability framework.

Industry Perspective: A Structural Realignment, Not Just a Compliance Update

Analysis shows this change signals more than a procedural adjustment—it reflects an evolving legal stance that treats the shipper as the anchor of end-to-end supply chain accountability. From an industry perspective, it accelerates the convergence of trade law with logistics finance and export credit risk management. What deserves closer attention is how quickly insurers, banks, and trade associations respond with standardized tools—such as endorsed insurance riders or model contract annexes—to help medtech exporters operationalize the new liability boundary. Observably, this may catalyze broader adoption of digital trade platforms offering real-time customs status tracking and automated release triggers.

Strategic Implications for Global Medtech Trade

This amendment does not alter technical standards or market access requirements—but reshapes the foundational risk architecture of cross-border medical equipment trade. It elevates contractual clarity, insurance adequacy, and buyer due diligence from best practices to core operational imperatives. For exporters, the takeaway is not increased restriction, but intensified responsibility: success will depend less on product capability and more on integrated trade compliance maturity.

Source Information and Ongoing Monitoring

This article was generated exclusively from the provided title, event date (1 May 2026), and summary. Specific official source links were not provided in the input and should be verified continuously. Stakeholders are advised to monitor forthcoming judicial interpretations, customs enforcement guidelines, and updates from China’s Ministry of Transport and Supreme People’s Court, as well as evolving practices among international banks and freight insurers regarding Article 93 implementation.